Lead Product(s) : Sacubitril-Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Alere Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure
Details : Sacubitril/Valsartan is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 27, 2019
Lead Product(s) : Sacubitril-Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Alere Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sacubitril-Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Medtronic Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD
Details : Entresto is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 12, 2017
Lead Product(s) : Sacubitril-Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Medtronic Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sacubitril-Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparing ARNI With ACE Inhibitor on Endothelial Function
Details : Sacubitril/Valsartan is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure, Systolic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 18, 2017
Lead Product(s) : Sacubitril-Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
